FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017304854> ?p ?o ?g. }

• W2017304854 endingPage "210" @default.
• W2017304854 startingPage "199" @default.
• W2017304854 abstract "Objective: To compare the lower osteoarthritis (OA) dose of rofecoxib to the recommended dose of celecoxib in two identically designed studies.Methods: Patients with knee OA were randomized (2:2:1 ratio: rofecoxib 12.5 mg once daily (qd), celecoxib 200 mg qd, or placebo, respectively). The primary endpoint was patient global assessment of response to therapy (PGART) averaged over 6 weeks on a five-point scale. Rofecoxib would be declared at least as effective as celecoxib if the lower bound of the 95% confidence interval (95% CI) for difference in means was no lower than –0.5. Additional endpoints included Pain and Physical Function subscales of the Western Ontario and McMaster (WOMAC) OA Index. Adverse experiences (AEs) were recorded and combined from the two studies for analysis.Results: Study 1 enrolled 395 patients (rofecoxib, n = 160; celecoxib, n = 157; placebo, n = 78). Study 2 enrolled 413 patients (rofecoxib, n = 159; celecoxib, n = 169; placebo, n = 85). Rofecoxib 12.5 mg was at least as effective as celecoxib 200 mg by PGART (Study 1 difference –0.09 [95% CI: –0.32, 0.14] and Study 2 difference 0.02 [95% CI: –0.20, 0.24]), and both were significantly ( p < 0.001) more effective than placebo. Comparable efficacy was also seen for WOMAC Pain and Physical Function subscales with the active treatments. There was a significantly higher ( p < 0.05) incidence of serious AEs with celecoxib than rofecoxib or placebo, none of which was drug-related. There were no significant differences in the pre-specified measurements of safety including drug-related AEs or discontinuations due to AEs, and the medications demonstrated similar safety as assessed by spontaneous reporting.Conclusions: Rofecoxib 12.5 mg and celecoxib 200 mg provided comparable efficacy over 6 weeks, and both were significantly more efficacious than placebo. The medications demonstrated similar safety compared to one another and placebo. The primary limitations of these studies were that they were only 6 weeks long and were powered for efficacy. Therefore, conclusions about long-term safety cannot be inferred." @default.
• W2017304854 created "2016-06-24" @default.
• W2017304854 creator A5000786936 @default.
• W2017304854 creator A5015704931 @default.
• W2017304854 creator A5027687514 @default.
• W2017304854 creator A5034041802 @default.
• W2017304854 creator A5056014905 @default.
• W2017304854 creator A5060426000 @default.
• W2017304854 creator A5078778411 @default.
• W2017304854 creator A5090460841 @default.
• W2017304854 date "2005-12-09" @default.
• W2017304854 modified "2023-09-30" @default.
• W2017304854 title "Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies" @default.
• W2017304854 cites W1983104516 @default.
• W2017304854 cites W1997642392 @default.
• W2017304854 cites W2022106950 @default.
• W2017304854 cites W2040872866 @default.
• W2017304854 cites W2055841596 @default.
• W2017304854 cites W2094345617 @default.
• W2017304854 cites W2115805053 @default.
• W2017304854 cites W2116728057 @default.
• W2017304854 cites W2117227343 @default.
• W2017304854 cites W2123366546 @default.
• W2017304854 cites W2130674238 @default.
• W2017304854 cites W2138361936 @default.
• W2017304854 cites W2158131645 @default.
• W2017304854 cites W2158968701 @default.
• W2017304854 cites W2161097107 @default.
• W2017304854 cites W2164290354 @default.
• W2017304854 cites W2330496155 @default.
• W2017304854 doi "https://doi.org/10.1185/030079906x80242" @default.
• W2017304854 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16393445" @default.
• W2017304854 hasPublicationYear "2005" @default.
• W2017304854 type Work @default.
• W2017304854 sameAs 2017304854 @default.
• W2017304854 citedByCount "21" @default.
• W2017304854 countsByYear W20173048542012 @default.
• W2017304854 countsByYear W20173048542013 @default.
• W2017304854 countsByYear W20173048542014 @default.
• W2017304854 countsByYear W20173048542015 @default.
• W2017304854 countsByYear W20173048542016 @default.
• W2017304854 countsByYear W20173048542017 @default.
• W2017304854 countsByYear W20173048542018 @default.
• W2017304854 countsByYear W20173048542020 @default.
• W2017304854 countsByYear W20173048542021 @default.
• W2017304854 countsByYear W20173048542022 @default.
• W2017304854 crossrefType "journal-article" @default.
• W2017304854 hasAuthorship W2017304854A5000786936 @default.
• W2017304854 hasAuthorship W2017304854A5015704931 @default.
• W2017304854 hasAuthorship W2017304854A5027687514 @default.
• W2017304854 hasAuthorship W2017304854A5034041802 @default.
• W2017304854 hasAuthorship W2017304854A5056014905 @default.
• W2017304854 hasAuthorship W2017304854A5060426000 @default.
• W2017304854 hasAuthorship W2017304854A5078778411 @default.
• W2017304854 hasAuthorship W2017304854A5090460841 @default.
• W2017304854 hasConcept C126322002 @default.
• W2017304854 hasConcept C142724271 @default.
• W2017304854 hasConcept C168563851 @default.
• W2017304854 hasConcept C181199279 @default.
• W2017304854 hasConcept C185592680 @default.
• W2017304854 hasConcept C197934379 @default.
• W2017304854 hasConcept C203092338 @default.
• W2017304854 hasConcept C204787440 @default.
• W2017304854 hasConcept C27081682 @default.
• W2017304854 hasConcept C2776164576 @default.
• W2017304854 hasConcept C2776467144 @default.
• W2017304854 hasConcept C2778582115 @default.
• W2017304854 hasConcept C2779286237 @default.
• W2017304854 hasConcept C2779689624 @default.
• W2017304854 hasConcept C42219234 @default.
• W2017304854 hasConcept C55493867 @default.
• W2017304854 hasConcept C71924100 @default.
• W2017304854 hasConceptScore W2017304854C126322002 @default.
• W2017304854 hasConceptScore W2017304854C142724271 @default.
• W2017304854 hasConceptScore W2017304854C168563851 @default.
• W2017304854 hasConceptScore W2017304854C181199279 @default.
• W2017304854 hasConceptScore W2017304854C185592680 @default.
• W2017304854 hasConceptScore W2017304854C197934379 @default.
• W2017304854 hasConceptScore W2017304854C203092338 @default.
• W2017304854 hasConceptScore W2017304854C204787440 @default.
• W2017304854 hasConceptScore W2017304854C27081682 @default.
• W2017304854 hasConceptScore W2017304854C2776164576 @default.
• W2017304854 hasConceptScore W2017304854C2776467144 @default.
• W2017304854 hasConceptScore W2017304854C2778582115 @default.
• W2017304854 hasConceptScore W2017304854C2779286237 @default.
• W2017304854 hasConceptScore W2017304854C2779689624 @default.
• W2017304854 hasConceptScore W2017304854C42219234 @default.
• W2017304854 hasConceptScore W2017304854C55493867 @default.
• W2017304854 hasConceptScore W2017304854C71924100 @default.
• W2017304854 hasIssue "1" @default.
• W2017304854 hasLocation W20173048541 @default.
• W2017304854 hasLocation W20173048542 @default.
• W2017304854 hasOpenAccess W2017304854 @default.
• W2017304854 hasPrimaryLocation W20173048541 @default.
• W2017304854 hasRelatedWork W1820127304 @default.
• W2017304854 hasRelatedWork W1961189376 @default.
• W2017304854 hasRelatedWork W1991350847 @default.
• W2017304854 hasRelatedWork W2017304854 @default.

• next